Global Human Fibrinogen Concentrate Market 2026 – 2035

Market Size and Growth

It is estimated that the market size of the global human fibrinogen concentrate will be USD 0.958 billion in 2025 and it is further estimated that the market size of the global human fibrinogen concentrate will increase to USD 1.06 billion in 2026 and reach approximately USD 2.78 billion in 2035 with the annual CAGR of 11.3% in the years 2026-2035.

An increase in bleeding disorders, including congenital fibrinogen deficiency and acquired coagulopathies, especially during trauma and surgery, is increasing the market. Demand is growing due to an increasing number of complex surgeries and emergency cases, which demand quick hemostasis.   

Market Highlight

• Asia Pacific was the market leader in human fibrinogen concentrate with a market share of 38.6%.

• North America: The growth will be 11.5% between 2026 and 2035.

• The form of lyophilized segment took the majority of the market in 2025, with it being about 65-70 percent because of quick reconstitution, extended shelf life, and a high rate of use in emergency and surgical bleeding management.

• Form The liquid segment is projected to grow fastest in the forecast period because of its ready-to-use nature and the growing use by the controlled clinical environment.

• End user-wise, the market share of the hospitals segment was the highest of 75-80% in 2025, as it would be motivated by the large volumes of surgery, trauma, and access to advanced critical care facilities.

• By end user, the ambulatory surgical centers segment will experience the highest growth rate as preferences for minimally invasive and outpatient procedures are on the rise.

• Indication-wise, the surgical procedures segment took the highest market share of approximately 40.58% in 2025, which is due to the high number of global surgeries and the necessity of fibrinogen in the management of hemostasis.

Significant Growth Factors

The Market Trends of the Human fibrinogen concentrate have a lot of growth opportunities because of the following reasons:

• Surging Cases of Bleeding Disorders and Rising Surgery: The increasing cases of both congenital and acquired bleeding disorders are a major motivation to the human fibrinogen concentrate market. Rapid replacement of fibrinogen is needed when using conditions like congenital fibrinogen deficiency and coagulopathy caused by trauma and massive hemorrhage. Clinical evidence indicates that congenital fibrinogen deficiency is a rare yet severe disease with a prevalence of about 1-2 people per million all over the world and thus needs specific treatment. Moreover, the rising number of surgical operations, which is projected to be more than 300 million surgical operations per year across the world, is a major driver of demand since often the fibrinogen becomes the first coagulation factor to fall to very low levels due to significant blood loss. Fibrinogen concentrate is a fast correcting agent, in contrast to the conventional plasma products, it saves on transfusion time and enhances patient outcomes, especially in the emergency and critical care units.

• Advantages Over Plasma-Based Therapies and Growing Adoption in Critical Care: Introduction Human fibrinogen concentrates are increasingly used in intensive care units because of their clinical and operational benefits as compared to traditional therapies, including fresh frozen plasma (FFP) and cryoprecipitate. These products have the advantage of standardized dosage, quick preparation (in minutes), and less risk of volume overload, important in patients who are critically ill. Research shows that in extreme cases of bleeding, the concentration of fibrinogen may reduce to unacceptable values (less than 1.5 g/L), and it must be treated immediately. In contrast to the plasma-based therapies, fibrinogen concentrates do not need the matching of the blood group and can be administered rapidly, which enhances the response rate in the emergency situations with trauma and obstetric hemorrhage. Also, they are increasingly being adopted as a result of reduced pathogen transmission risks and better safety records. The emergence of increased awareness among the clinicians, recent developments in the field of plasma fractionation, and the enhancement of hospital practices are also contributing to the increased use of fibrinogen concentrates in emergency medicine, cardiac surgery, and trauma care in the world.

What are the Major Advances Changing the Human fibrinogen concentrate Market Today?

• Recombinant and High-Purity Plasma-Derived Products: Recombinant and High-Purity Plasma- Derived products are one of the most dramatic changes in the market of human fibrinogen concentrates. These innovations enhance safety, uniformity, and supply as opposed to the traditional blood components like cryoprecipitate. Purified viral inactivation and purification processes are also developed on modern fibrinogen concentrates, which is why the levels of transmission of certain pathogens are reduced significantly. Fibrinogen is the first factor to be reduced to critical levels (less than 1.520 g/L) when it comes to major bleeding, so the replacement cannot be done quickly enough. Recombinant technologies will also deal with the constraints in supply that are accompanied by plasma donation so that there is greater accessibility. Such developments allow standardization of doses, enhanced pharmacokinetics, and accelerated clinical response, and thus fibrinogen concentrates are a preferred choice in the management of trauma, cardiac surgery, and obstetric hemorrhage.

• POC Coagulation Testing and Targeted Therapy: The combination of point-of-care (POC) diagnostic systems, including viscoelastic testing (e.g., ROTEM and TEG), is changing the concept of fibrinogen therapy. The systems offer real-time evaluation of the formation of clots and the fibrinogen amounts and therefore assist clinicians in making prompt evidence-based decisions in case of critical bleeding events. Research demonstrates that POC-directed targeted fibrinogen replacement can help to decrease unwarranted transfusion and enhance patient outcomes. Early use of fibrinogen supplementation has been identified to reduce mortality risk in severe trauma cases. This empirical to goal-based therapy change ensures that patients are accurately dosed according to factual deficiency and that complications such as over-transfusion and fluid overload are reduced. Consequently, the use of fibrinogen concentrates is being introduced into the standardized bleeding management practice increasingly in hospitals.

• Lyophilized Formulations and Rapid Reconstitution: The technology of formulation and packaging has led to better utilization of fibrinogen concentrates both in the emergency room and in the operating room. In the case of modern products, they are in a freeze-dried (lyophilized) state to enable quick reconstitution in a few minutes in emergency bleeding scenarios that may cause death. Fibrinogen concentrates have the ability to be stored at controlled room temperatures and administered expeditiously without compatibility delays, unlike traditional plasma products, which require thawing and blood group matching. This is a great way of saving time in the treatment of trauma, military medicine, and emergency care. It also leads to a better shelf life and increased stability, thus leading to a reduction in wastage and improved inventory management in hospitals. These characteristics make fibrinogen concentrates very appropriate to be used in clinical settings that have a time constraint, whereby any delay in intervention means patient loss.

• Expansion of Clinical Applications and Evidence-Based Guidelines: Another significant improvement is an increased amount of clinical evidence to attest to the use of fibrinogen concentrates in a broader collection of indications. Fibrinogen concentrates are initially used in rare hereditary deficiencies but nowadays are commonly used in traumatology, cardiothoracic surgery, liver surgery, and postpartum hemorrhage. Clinical practices are growing in support of keeping fibrinogen above 1.5 to 2.0 g/L in the event of active bleeding so that the clot can form properly. Early fibrinogen replacement has been observed to decrease massive transfusion in obstetric hemorrhage. Also, research indicates that the supplementation of fibrinogen has the potential to enhance the strength of the clot and minimize the complications of bleeding. The growing clinical acceptance of this is being aided by standardized treatment protocols as well as leading to greater adoption and establishing fibrinogen concentrates as an essential element of modern hemostatic management.

Category Wise Insights

By Form

Why Lyophilized Form is the best in the market?

Lyophilized form of fibrinogen concentrate is the most significant share of the human fibrinogen concentrate market mainly because it is very critical in emergency and surgical care premises where there is a need to act fast. Lyophilized fibrinogen is very attractive since it can be reconstituted fast, say within minutes, so that it can be used immediately during the occurrence of acute bleeding like trauma, cardiac, and postpartum bleeding. In clinical terms, the initial coagulation factor to reach critical levels (usually below 1.520 g/L) is fibrinogen in case of major bleeding, and therefore, prompt replacement is important. Its shelf stability and the capacity not to undergo complicated freezing conditions increase the hospital inventory system and save wastage. Moreover, standard dosage and enhanced safety profiles over conventional plasma products are other reasons that contribute to its supremacy. Ready-to-use liquid forms are restricted by reduced shelf life and tougher storage requirements, whereas less frequent dosage is used in powder forms because of slower preparation and reduced clinical popularity.

 By End User

Why Do Hospitals Dominate the Market?

The human fibrinogen concentrates market is dominated by hospitals since the majority of complicated operations and emergency care cases are handled in the hospitals. Over 300 million surgical operations are done annually globally, most of which involve the need to deal with a lot of bleeding and coagulation. The main providers of trauma care are hospitals, where in severe bleeding, a great part of emergency cases is represented by the need to replace fibrinogen in a short period of time as a part of transfusion procedures. Availability of sophisticated diagnostic equipment, including the viscoelastic tests, facilitates the administration of fibrinogen concentrates in time and with accuracy, thus enhancing the results of the patients. Besides, hospitals possess dedicated staff and resources to manage high-risk cases, such as organ transplant and significant cardiovascular operations. Minimally invasive procedures are increasing the expansion of the Ambulatory Surgical Centers which have restricted application in critical bleeding cases. Other healthcare environments also have a lesser contribution because of less complexity in the procedure and fewer emergency facilities.

 By Indication

What Makes Surgical Procedures Ruler of the Market?

Surgical operations constitute the biggest indicator segment in the market of human fibrinogen concentrate due to the necessity of sustained hemostasis in operation and post-operative processes. During large surgical operations like heart operations, orthopedic, and liver surgeries, the level of fibrinogen may be decreased very quickly, making it more prone to too much bleeding. According to clinical guidelines, it is imperative to keep fibrinogen levels above 1.52 g/L in order to promote clot formation and minimize the occurrence of complications. As the world surgery rate is more than 300 million per year, the rate of need to have quick and dependable coagulation treatment keeps on increasing. Fibrinogen concentrates are becoming more popular compared to the conventional blood components because of the fact that they are prepared quickly, the dosage is always standardized, and transfusion-related complications are less likely to occur. Although congenital fibrinogen deficiency is also an important disease entity, it is a relatively small category since it is a rare condition that occurs in few people per million in the population, but it must be managed through continuous and lifelong treatment.

Report Scope

Regional Analysis

Why was Asia Pacific in Dominance of the Market in 2025?

The market of the human fibrinogen concentrate is mainly leading in the Asia Pacific, due to the high base of the patients, growing surgical procedures, and growing accessibility to advanced healthcare. The area has a high number of cases of trauma in the world, where soft tissue injuries alone have a large number of cases of emergency hospitalization involving urgent bleeding management.

The region is experiencing a rapid aging of the population, and the growing population of the elderly population is predicted to go past 600 million by 2030, which poses a risk of developing surgical complications and coagulopathies. Also, the increasing rates of obstetric hemorrhage, which is one of the causes of maternal mortality in the developing world, are increasing the demand for fibrinogen therapy. The market is also getting dominated throughout the Asia Pacific through the expansion of healthcare infrastructure, rise in the government expenditure on healthcare, and enhanced access to critical care treatments.

China Market Trends

China is one of the biggest markets with developing healthcare facilities and volume of surgery. Millions of surgeries are done every year in the country, and the use of the advanced hemostatic products is being adopted more in the tertiary hospitals. The fact that the aged population is over 200 million and consists of 65 and over years of age is a significant factor that increases surgical and trauma-related risks. Also, there is the increasing trend in the cases of liver diseases and cardiovascular conditions that necessitate the management of coagulation effectively. The accessibility and cost reduction is being enhanced by government investment in hospital infrastructure and the production of plasma-derived therapies in the country.

What is the Reason why North America is Achieving a Constant Growth?

The growth of North America is steady since it is enjoying a high level of clinical adoption, a sophisticated healthcare system, and awareness among the healthcare professionals. Trauma cases and surgical operations are high in the region, and hemorrhage is one of the top causes of death amongst trauma cases that could be prevented. The preemptive fibrinogen infusion is also becoming a part of the transfusion guidelines. Moreover, a properly developed set of guidelines and the prevalence of point-of-care diagnostic devices contribute to the targeted use of fibrinogen. Market growth is also enhanced by the existence of major biopharmaceutical companies and the ongoing research.

How big is the U.S. Market?

The human fibrinogen concentrate market in the U.S. is enhanced by the high number of surgeries and cases of trauma. Having more than 40 million inpatient surgical operations each year and a high level of patient care, the need to find fast and efficient bleeding management systems is still great. Fibrinogen concentrates are gaining acceptance in hospitals that are progressing to standardized and targeted coagulation treatment.

U.S. Market Trends

Advanced clinical practices, the rising trauma incidence, and the augmented use of goal-directed therapy are the forces in the U.S. market. The proportion of deaths caused by hemorrhage is a large percentage of deaths caused by trauma, and as such, prompt intervention is necessary. The application of viscoelastic testing in hospitals to be able to administer fibrinogen is gaining prominence and is yielding better results and lessening unnecessary transfusion. Also, effective reimbursement models and continuous clinical studies are facilitating the further implementation of fibrinogen concentrates in surgical and emergency care models.

What motive does Europe have in the Concentration of Efficiency and Clinical Standardization?

The European market is still a major one because of its aging population and high focus on evidence-based medicine. Over 20 percent of the population of most European countries is aged 65 years and more, which predisposes them to surgeries and bleeding conditions. The region adheres to strict clinical guidelines that encourage the use of fibrinogen replacement early in the major bleeding cases. The consistency in demand is being propelled by the public healthcare systems and standardized treatment procedures. Also, emphasis on effective use of resources is promoting fibrinogen concentrate usage as compared to conventional plasma products.

Germany Market Trends

Germany is a market leader in Europe, as it has high quality healthcare facilities and embraces coagulation therapy. The nation carries out a high rate of complicated surgeries each year and has well-built transfusion guidelines, which consist of fibrinogen supplementation. Well-developed reimbursement system and focus on quality medical care promote market growth. The adoption of point-of-care diagnostics and precision medicine approaches is also increasing, which strengthens their adoption even in Germany.

What is the reason why the Middle East & Africa Region is undergoing Growth?

The Middle East & Africa region is on the path of growth because of the enhanced healthcare structure and the rising awareness of critical care management. Increased trauma, road accidents, and surgical operations are also driving the need to have an effective solution to bleeding. Healthcare expenditure in various gulf nations is rapidly growing, which justifies the implementation of new treatment methods. Also, maternal hemorrhage is still one of the critical issues in certain regions of Africa, which prompts the demand to replace fibrinogen. The market remains nascent; however, continued investment in the healthcare systems and the increased access to advanced treatment are likely to provide the market with consistent growth.

Top Players in the Market and Their Offerings

• CSL Behring

• Octapharma AG

• LFB Group

• Grifols S.A.

• Shanghai RAAS Blood Products Co. Ltd.

• Hualan Biological Engineering Inc.

• Harbin Pacific Biopharmaceutical Co. Ltd.

• Green Cross Corporation

• Shanghai XinXing Medical

• Jiangxi Boya Bio-Pharmaceutical Co. Ltd.

• Baxter International Inc.

• Kedrion Biopharma Inc.

• Biotest AG

• Sanquin Blood Supply Foundation

• China Biologic Products Holdings Inc.

• BPL (Bio Products Laboratory)

• Kamada Ltd.

• ProMetic Life Sciences Inc.

• Beijing Tiantan Biological Products Co. Ltd.

• Scripps Laboratories.

• Others

Key Developments

The market has gone through significant evolution as market players are trying to expand the capabilities and product offerings.

• According to BioTest, positive Phase III clinical data of its fibrinogen concentrate Phase III candidate BT524 was reported in June 2025, with the candidate demonstrating that it was not inferior to the standard of care (SOC). The findings were presented in the water journal eClinicalMedicine, which showed the efficacy and security of BT524 in the management of bleeding illness and enhanced its application as a legitimate alternative in the treatment of coagulation.

• In July 2024, the U.S. Food and Drug Administration approved a human fibrinogen concentrate that was developed by Octapharma to treat acquired fibrinogen deficiency (AFD), a severe illness, to allow the formation of blood clots, which causes a person to be at risk of severe bleeding. It is the first treatment approved by the FDA specifically mentioned in the management of AFD that is a significant advancement in the management of bleeding disorders.

These are planning processes that have helped the companies to have a solid market standing, product diversification, enhancement of technological capabilities, and exploitation of the opportunities of the expanding market.

The Human Fibrinogen Concentrate Market is segmented as follows:

By Form

• Lyophilized

• Powder

• Liquid

By End User

• Hospitals

• Ambulatory Surgical Centers

• Others

By Indication

• Surgical Procedure

• Congenital Fibrinogen Deficiency

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America